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Effects of Medication Use on Health State 
in Postictal Migraineurs
 
E.J.C.M. Mulder, PhD; J. Passchier, PhD; W.H.J.P. Linssen, PhD, MD; E.J.C. de Geus, PhD
 
We investigated whether headache-free patients with migraine report a lower health state compared with
healthy controls, and whether health state is differently affected during the postattack period after using sumatrip-
tan versus habitual nonvasoactive medication. Mood, health state, and personality questionnaires were adminis-
tered once during an interictal period and twice within 30 hours after different migraine attacks treated with
sumatriptan or habitual nonvasoactive medication. Twenty migraineurs without aura, 10 migraineurs with aura,
and 30 matched and headache-free controls participated in this study. During an interictal period, patients with
migraine reported more problems regarding social activities and pain compared with healthy controls. During the
postictal period, mood (fatigue and emotional state) was negatively affected by an attack that was treated with habit-
ual medication, whereas health state (physical pain, social activities, current pain) was similar to the migraine-free
period. Sumatriptan treatment had beneficial effects on aspects of health state and mood during the postictal period.
Key words: migraine, health state, interictal, postictal, sumatriptan
Abbreviations: DPQ Dutch Personality Questionnaire, AMT Achievement Motivation Test, STAI Spielberger
State-Trait Anxiety Inventory, STAI-1 state anxiety inventory of the STAI, STAI-2 trait anxiety
inventory of the STAI, NHP Nottingham Health Profile, NHP1 health-related quality-of-life sec-
tion of the NHP, NHP2 impairment of daily life activities section of the NHP, CW COOP-












which comprises physical complaints, psychological
functioning and well-being, social disability, role dis-





tween attacks, during normal physical health, mi-
graineurs perceive greater emotional distress, and





 The lower perceived health state
in migraineurs is manifested by problems with pain,




 and can partially be
explained by a different personality structure or mood
state, and partially by psychological effects of the expo-
sure to the repeated and debilitating migraine attacks,
and living in anticipation of an upcoming attack.
Migraineurs have been stereotyped as obsessional,





 Recent studies based on clinic and conve-
nience samples demonstrated that patients with mi-














tion-based studies have corroborated elevated levels





 It is unclear to what extent these char-
acteristics are associated with perceived health state.
A migraine attack can also directly affect health
state. This is most apparent during the attack, which
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can be accompanied by autonomic symptoms such as
visual or sensorimotor disturbances; yawning; food










 Changes in health state can also be found
preceding an attack. An increase in irritability, an-
noyance, and tenseness has been found up to 60
hours preceding a migraine attack, as well as a





 Hypersensitivity to light, sound, or smell; al-
tered mood state; and tiredness can persist until




 suggesting that health state
can be influenced during the postattack period. The
extent of this influence could be dependent on attack
duration, severity, or medication use. To explore this,
we examined health state during a postattack period
after sumatriptan use and during a postattack period
after habitual nonvasoactive medication (ie, nonste-





 receptor agonist and is effec-





study addresses three questions: first, whether inter-
ictal and headache-free patients with migraine have a
lower health state compared with healthy controls
and how this is related to mood state and personality
traits; second, whether the postictal period is accom-
panied by an impaired health and mood state; and
third, whether postictal health and mood state is af-







Thirty patients with migraine (20 with-
out aura, 10 with aura) and 30 matched healthy con-
trols participated in the study. All were students and
were recruited by advertisements in university papers.
Patients were diagnosed by a neurologist in accor-





 physically examined, and entered into the
study. Patients using prophylactic medication, monoam-





inhibitors, or lithium, and patients with a known hyper-
sensitivity, intolerance, or contraindication to the use
of sumatriptan were excluded from the study. All pa-
tients had used sumatriptan at least once before par-
ticipation in the laboratory sessions. Control subjects
were selected from the same student population and
matched to patients with migraine on the basis of
gender, age, and handedness. Socioeconomic status
was comparable between patients and control sub-
jects. Controls did not suffer from migraine and did
not suffer from any other type of headache more than
once per 2 months (eg, due to alcohol consumption
or exposure to toxic substances). Subjects were not
admitted to the study if they had a history of epilepsy;
possible risk of structural brain lesions or other se-
vere medical conditions which could affect the inter-
pretation of the results; current abuse of opiate analge-
sics, psychotropic drugs, ergotamine (more than 10 mg
per week), or alcohol (more than 315 g per week); or





After receiving verbal instructions on
how and when to complete the personality question-
naires, all subjects filled out a set of personality ques-
tionnaires at home on a headache- and symptom-free
day. These are self-administered questionnaires and
validated as such, and all contain written instructions.
We cannot exclude, however, an effect of the absence
of a supervising experimenter on the test scores. Both
patients and controls completed mood and health
state questionnaires at the beginning of three ses-
sions. The patients with migraine were tested follow-
ing three different attacks. The first session took
place on a headache- and symptom-free day, 4 or 5
days after the peak of a migraine attack. If the first
session was followed by a new migraine attack within
3 days, that session was considered invalid. The sec-
ond and third sessions each took place within 30
hours after a migraine attack and after 1 proper
night’s rest, after which the headache severity had de-













severe). During one of
these two attacks directly followed by a postattack
session, patients with migraine treated the attack with
a 100-mg sumatriptan tablet. During the other attack,
patients used their habitual migraine medication,
which could also be no medication. The order of ha-
bitual medication use or sumatriptan use was coun-
terbalanced over the second and third attacks.
Due to test habituation and learning effects, re-






that can confound interictal to postictal changes.
Therefore, the inclusion of control subjects who are
also repeatedly tested is necessary to identify possible
postattack effects. Control subjects were tested while
headache-free and without having used medication
during the same period of the week (beginning, mid-
dle, weekend) and at the same time during the day
(morning, afternoon, evening) as the patient they
were matching. Furthermore, the intervals between
the control sessions were equivalent to the test inter-




The assessment comprises ques-
tionnaires for health state, mood state, and personality




The Dutch Personality Ques-




of the California Psychological Inventory. The follow-
ing scales were administered: (1) inadequacy (vague
physical complaints but no specific headache symp-
toms, depressed mood, nonspecific anxiety, and feel-
ings of insufficiency; this scale is considered a mea-
sure for neuroticism); (2) rigidity (a preference for
having control over situations and having fixed habits
and principles); (3) resentment (being critical and
distrusting towards others); and (4) self-evaluation
(positive attitude towards work, being flexible, and





 measures achievement motivation (the drive
to excel in challenging situations), debilitating anxi-
ety (anxiety which leads to dysfunctioning in tasks
which are relatively unstructured and personally rele-
vant), and facilitating anxiety (stress tolerance or anx-
iety which leads to optimal functioning in relatively
unstructured personally relevant tasks). The Dutch




















generic instruments for multidimensional health state
assessment that measure physical, psychological, and
social functioning which are relevant for the health
state of both patients and healthy controls. The NHP
consists of statements regarding problems that can be
encountered in daily life. The first part of the NHP
(NHP1) denotes health-related quality of life and
consists of 38 dichotomous items, covering the do-
mains of energy, pain, emotional reactions, sleep, so-
cial isolation, and physical mobility. In accordance
with the manual, standardized subscores were com-
puted and analyzed. The second part (NHP2) denotes
the amount of impairment that the current health
state inflicts on daily life activities (employment, jobs
around the house, social life, personal relationships at
home, sex life, leisure time, and holidays). The NHP








 of the CW charts is an in-
strument for the self-report of functional status and
contains a set of functional aspects of daily life expe-
rienced in the 2 weeks prior to completion. The items
are emotional problems (such as anxiety, depression,
irritability, or dejection), physical fitness (most ex-
treme exertion that could be kept up for at least 2
minutes), daily activities (difficulties during daily ac-
tivities in and around the house due to physical or
emotional problems), social activities (hindrance in
social activities with family, friends, neighbors, or
club members due to physical or emotional prob-
lems), general health, change of health (compared
with 2 weeks before), and physical pain. All items
cover a period of 2 weeks prior to completion, except
for physical pain which covers the previous 4 weeks.
The levels on the scales are illustrated with picto-






















 very much). The levels for general health are





























was administered for the assessment of situational


























 contains the fol-
lowing scales: Depression/Dejection, Anger/Hostility,
Fatigue/Inertia, Vigor/Activity, and Tension/Anxiety.
Subjects marked the degree to which their mood


























This study was part of a larger pro-






tive testing and electroencephalogram measurements
performed after the subjects completed the question-
naires. All subjects abstained from alcohol, tobacco,
and caffeine during the hours prior to testing and
during the testing procedure. Each laboratory session
began with completion of a visual analog scale that
determined the headache severity of the preceding
migraine attack on a line representing a 0 to 100
scale. The extremes of pain were “no pain” and “as
bad as it could be.” At the beginning of each session,
the number of hours that had passed after meaningful
relief from the migraine headache and after medica-
tion intake was determined, based on the diaries that
were kept during the attack. Duration of a migraine
attack was determined by a single question: “How




Two patients with migraine (one
with aura, one without aura) left the study after the
second session and consequently had a missing post-
attack session after usual medication use. These miss-
ing values were replaced by the scores these subjects
had during the postattack session after sumatriptan.
Two control subjects dropped out after the first ses-
sion, while the matching patients with migraine par-
ticipated in all sessions. These missing data were re-
placed by the session means of all control subjects.
Two control subjects did not complete the personal-
ity questionnaires, and these missing values were re-
placed by the group means.
 
Data Reduction and Analyses.—
 
The session char-
acteristics listed in Table 1 were submitted to analysis
of variance (ANOVA) for repeated measures. These




(postattack session after sumatriptan use, postattack





 (migraineurs with aura, migraineurs
without aura). Because we individually matched pa-
tients with migraine and healthy controls on a range
of subject-related characteristics (sex, dominant hand,
and age) as well as session-related characteristics
(part of the day and weekday at which testing took
place), we submitted all variables listed in Table 2 to
ANOVA for paired observations. More specifically,
a patient with migraine and the matched control were





 (migraineurs, controls). In order to
group the patients into migraineurs with aura and mi-





 (migraineurs with aura,
migraineurs without aura). First, we compared mi-
graineurs to controls in the baseline session and per-









 (migraineurs with aura, migraineurs without
aura). Second, we compared the baseline session to
the postictal sessions between migraineurs and con-





 with three levels (baseline session,
postattack session after sumatriptan use, postattack
session after usual medication use). We entered all
sessions into ANOVA for repeated measures with









 (baseline session, postattack session after
 

















Women/men, No. 8/2 18/2
Left-/right-handed, No. 1/9 4/16
Age, y 24.3 (4.9) 24.9 (2.8)
Migraine history, y 7.1 (3.8) 6.2 (3.7)
Attack duration, h†,‡
Sumatriptan 7.6 (4.7) 10.7 (12.1)






67 (19) 83 (11)
Sumatriptan 61 (29) 74 (17)
Usual medication 64 (21) 71 (19)
Interval medication intake 
and session, h
Sumatriptan 23.1 (8.5) 21.8 (8.1)
Usual medication 26.5 (8.4) 25.8 (13.4)
Interval meaningful relief
and session, h
Sumatriptan 17.7 (9.9) 16.2 (7.7)
Usual medication 14.8 (8.1) 12.5 (7.0)
*Values are means (SD) unless otherwise indicated.
†Attack duration is determined by the number of hours
between the prodromal state and meaningful relief.












Significant difference between migraineurs with aura and












sumatriptan use, postattack session after usual medica-





graineurs with aura, migraineurs without aura). This
implies that each case contained six observations for
each variable. If no differences were detected be-




 was excluded from
the model. Pearson correlations were used to de-
scribe the interrelations between mood, personality,
and health state variables during the baseline session.
We hypothesized that patients with migraine have
higher scores compared to controls on indicators of
neuroticism, fatigue, tension, rigidity, and resentment,
all scales of the AMT, and have lower scores on vigor,
health state, and self-evaluation. During the postat-
tack sessions, we expected that these group differ-
ences would be smaller after sumatriptan use than
after usual medication intake. Therefore, these spe-
cific effects were tested one-tailed. If postictal effects
were present in migraine patients, these would be re-




















 interactions. One-tailed follow-up tests ensued
the detection of these significant interactions. Uni-





We reduced type I error within families of tests




 Before we proceeded
with the actual ANOVA, we clustered the variables
into families of tests. First, we considered the base-
line session and the postattack-related changes as dif-
ferent research questions; these are reported sepa-
rately for this reason. Second, we grouped all variables
that we extracted from the baseline session into six
clusters, as listed in Table 2. According to the Holm




 did not ex-
ceed .05 after multiple statistical testing within each
family of tests. We constructed four clusters for the
ANOVAs involving all three sessions: health state
(NHP1), health state (CW), impairment of daily ac-
tivities (NHP2), and mood (POMS and state anxiety
[STAI-1]). We also used the Holm Method for these
analyses and for the follow-up tests.
Levene tests were executed to ensure that the as-
sumption of homogeneity of variances between groups
was met, if necessary after a transformation of the de-
pendent variable. For this purpose, a square root trans-
formation was executed on “attack duration,” and the
data of two patients with migraine were removed and
replaced by the group means of “attack severity.”
Moreover, a logarithmic transformation was executed
on the NHP2 sum scores and a square root transfor-
mation on the POMS subscales.
 
Table 2.—Health Status, Mood, and Personality in Patients 















Pain 2.5 (7.6) 0 (0)
Energy 14.4 (27.2) 4.6 (19.0)
Sleep 12.0 (18.6) 6.9 (21.2)
Social isolation 6.7 (15.2) 4.8 (12.5)
Emotional reactions 8.1 (12.5) 4.4 (10.6)
Impairment daily activities
(NHP2)
0.6 (0.7) 0.1 (0.4)
Health status (COOP-WONCA)
Physical fitness 1.7 (0.7) 1.5 (0.7)
Daily activities 1.8 (1.0) 1.4 (0.6)
Social activities† 1.8 (1.0) 1.2 (0.5)
General health 2.6 (1.0) 2.3 (0.9)
Change in health† 2.9 (0.8) 2.5 (0.7)
Physical pain† 3.1 (1.0) 1.8 (1.0)
Dutch Personality Inventory
Inadequacy 12.1 (8.0) 12.3 (7.2)
Rigidity† 23.3 (6.7) 17.8 (7.2)
Resentment 14.1 (7.6) 13.8 (5.0)
Self-evaluation 28.4 (6.7) 28.5 (6.4)
Achievement Motivation Test
Achievement motivation† 22.0 (5.9) 18.2 (6.4)
Debilitating anxiety 11.6 (5.7) 12.0 (6.0)
Facilitating anxiety 11.8 (4.4) 11.8 (4.0)
Anxiety
Trait anxiety (STAI-2) 37.2 (8.6) 36.3 (9.0)
State anxiety (STAI-1) 32.6 (6.2) 32.0 (4.8)
Profile of Mood States
Depression 0.6 (1.1) 0.4 (0.7)
Anger 0.7 (1.0) 0.6 (0.7)
Fatigue 1.4 (1.1) 1.2 (1.1)
Vigor 2.7 (0.9) 2.9 (0.8)
Tension 1.3 (0.8) 1.3 (1.0)
*Values are means (SD). NHP1 indicates the first part of the
Nottingham Health Profile (NHP); NHP2, the second part of
the NHP; STAI-2, the trait anxiety section of the Spielberger
State-Trait Anxiety Inventory (STAI); STAI-1, the state anxi-
ety section of the STAI. NHP2 is a summed score.





























Demographics and Session Characteristics.—
 
Ta-
ble 1 depicts the demographics and session character-
istics of the patients with migraine with aura and the
patients with migraine without aura. Age and mi-
graine history were comparable between the groups.
The headache severity of general attacks was higher













.008), but headache severity was
not significantly different during the attack treated
with sumatriptan compared with the attack treated
with usual medication. Attack duration was short-













.002). The time interval
from medication intake to the start of the following
postattack session for the two different types of med-
ication was not significantly different; the number
of hours between meaningful headache relief after
both types of medication and the start of the subse-
quent postattack sessions was also not significantly
different.
 
Interictal Migraineurs Versus Controls.—
 
Table 2
lists the means of health state, mood, and personality





—During the interictal session, mi-
graineurs reported a higher health-related impair-













compared with controls, and more severe problems


























with controls, migraineurs reported worse health






















5.6, P.013) and achievement motivation
(F1,284.9, P.016) compared with control subjects.
Association Between Mood State and Health State
in Patients With Migraine.—Table 3 lists the Pearson
correlations between aspects of health state, mood
state, personality, and migraine characteristics. In mi-
grainous patients, mood state, rather than personality




















(NHP1) History Duration Severity
Mood states
Depression .13 .41 (.02) .15 .54 (.00) .69 (.00) .36 (.05) .27 .13 .09
Fatigue .09 .38 (.04) .03 .48 (.01) .52 (.00) .44 (.01) .17 .28 .21
Anxiety .19 .57 (.00) .08 .64 (.00) .48 (.01) .38 (.04) .27 .50 (.01) .21
Anger .19 .19 .04 .39 (.03) .38 (.04) .25 .23 .33 .08
Vigor .05 .20 .02 .48 (.01) .21 .08 .05 .45 (.01) .11
Tension .11 .17 .03 .10 .36 (.05) .14 .34 .25 .13
Personality
Inadequacy .19 .03 .05 .23 .52 (.03) .13 .13 .06 .12
Rigidity .14 .01 .07 .09 .26 .20 .25 .03 .18
AM .12 .15 .02 .07 .06 .16 .08 .44 (.02) .17
Health state
Current pain .12 .56 (.00) .12 .40 (.03) .58 (.00)  .11 .07 .19
Attack characteristics
History .01 .13 .54 (.00) .13 .13 .11  .03 .32
Duration .22 .16 .03 .34 .09 .07 .03  .20
Severity .06 .02 .16 .23 .09 .19 .32 .20 
*Values are Pearson correlations (P.05) between health state, mood state, personality variables, and attack characteristics in 20
migraineurs without aura, 10 migraineurs with aura. AM indicates achievement motivation; NHP1, Nottingham Health Profile:
health status; NHP2, Nottingham Health Profile: impairment in daily activities; CW, COOP-WONCA charts; history, years of
migraine history; duration, attack duration after habitual medication intake; severity, general headache severity.
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measures, was significantly associated with health
state. High levels of depression, fatigue, and anxiety
were accompanied by more problems regarding so-
cial activities, general health, energy, and current
pain. Correlations for control subjects are not listed
because none of these were significant, except for the
correlations between achievement motivation and so-
cial activities (R.43; P.018), and fatigue and en-
ergy (R.40; P.028).
Differences Between Migraineurs and Controls
During All Sessions.—Health State.—Main pair ef-
fects indicated that, compared with controls, patients
with migraine report more impairments in the execu-
tion of daily life activities (NHP2: F1,2923.3, P.000)
and more severe complaints regarding energy (NHP1:
F1,29 8.2, P.004), general physical pain (CW: F1,29
44.5, P.000), social activities (CW: F1,29 8.1, P.008),
and general health (CW: F1,29 7.9, P.005). Compared
with controls, migraineurs reported worse general
health than 2 weeks prior (CW: F1,29 12.4, P.001).
Mood State.—Migrainous patients showed lower
levels of vigor (POMS: F1,294.1, P.05) compared
with controls. Migraineurs with aura showed higher
levels of tension (POMS: F1,286.2, P.025), anger
(POMS: F1,286.7, P.025), and anxiety (STAI-1:
F1,288.8, P.017) than controls.
Baseline Versus Postattack Sessions.—Health State.—
The Figure depicts the trends for pairsession inter-
Health status in migraineurs during interictal and postictal sessions. Mean scores of aspects of health state in patients with migraine
(bold lines) and matched healthy control subjects (normal lines) during the interictal (baseline) measurement, the postattack ses-
sion after sumatriptan use, and the postattack session after habitual (usual) medication use.
Headache 789
action effects which were detected for current pain
(NHP1: F2,582.5, P.046), general physical pain (CW:
F2,583.5, P.018), social activities (CW: F2,493.8,
P.018), and general emotional problems (CW: F2,58
2.2, P.034). Follow-up tests showed that the baseline
disadvantages in migraineurs compared with controls,
are unaltered during the postattack period after usual
medication use and significantly reduced during the
postattack period after sumatriptan use (current pain
NHP1: F1,293.9, P.029; general physical pain CW:
F1,297.4, P.006; and social activities CW: F1,293.8,
P.030). Furthermore, the relatively worse emotional
state in interictal migraineurs was unaltered during
the postattack period after sumatriptan use, but wors-
ened after usual medication use (CW: F1,295.0, P
.017).
Mood State.—A significant pairsession interac-
tion was found for fatigue (POMS: F2,583.4, P.020).
Follow-up testing showed that the baseline difference,
with higher levels of fatigue in migraineurs than controls,
was unaltered in the postictal period after sumatriptan
use and significantly more enhanced when usual medica-
tion had been used (F1,296.9, P.007).
COMMENTS
Headache-free patients with migraine reported a
lower health state compared with healthy control
subjects, which has also been found in other stud-
ies.1,3,24 Mood and health state are interrelated con-
cepts that can both be a source of hindrance in daily
functioning. This confounds the determination of
what causes the perceived lower health state in mi-
graineurs. In the following, we refer to mood state as
“internalizing” aspects of health state and to the par-
ticipation in daily and social activities as “externaliz-
ing” aspects of health state. We demonstrated that
migraineurs report higher levels of impairment in the
externalizing aspects of health state. They reported
more problems in the execution of daily activities,
more severe problems regarding physical pain and
participating in social activities, and worse general
health compared with controls. It was only in patients
with migraine that aspects of mood state were strongly
associated with externalizing health state. More prob-
lems concerning current pain, energy, general health,
and participation in social activities were strongly as-
sociated with higher levels of state fatigue, depres-
sion, and anxiety. A longer migraine history, a higher
general headache severity, and attack duration were
not accompanied by negative effects on internalizing
or externalizing aspects of health state. This suggests
that being a migraineur per se or living in anticipation
of an upcoming attack is probably related to an im-
paired health state in headache-free migraineurs.
This impaired health state could be associated
with certain personality factors that are associated with
migraine. In the present study, migraineurs showed
higher levels of rigidity and achievement motivation
compared with their healthy controls, which has also
been found in other studies.6,7 As shown in Table 3,
these personality traits did not play a decisive role in
the perception of an impaired health state, but the
causal relationship between migraine, rigidity, and
achievement motivation remains unclear. These per-
sonality factors might predispose or increase the risk
of the development of migraine, or could mirror a
psychological reaction to the repeated and unpredict-
able exposure to migraine and its incapacitation. We
suggest that the longer a migraine attack lasts, the
more achievement-oriented one is in a migraine-free
period to make up for this lost time. Unlike achieve-
ment motivation, rigidity was not associated with at-
tack duration, severity, or length of migraine history.
Increased levels of rigidity might, therefore, be part
of a certain predisposition to migraine or a conse-
quence of living in constant anticipation of an attack.
During the migraine-free period, mood state is
similar in migraineurs and healthy controls. Aver-
aged over the sessions, we demonstrated that mi-
graineurs with aura show higher levels of tension, an-
ger, and anxiety. This result supports the study of
Merikangas et al25 who found higher levels of neurot-
icism, predominantly in migraineurs with aura. The
present study could not confirm the high levels of de-
pression that have been demonstrated in migraineurs,8
which could be due to the relatively young sample of
patients with migraine recruited in a student popula-
tion. The fact that higher levels of tension, anger, and
anxiety in migraineurs with aura were only found if in-
terictal and postictal sessions were averaged, stresses
the importance of controlling for the time interval be-
tween a preceding attack and an interictal measurement.
790 September 2001
The postattack session after an untreated attack
or an attack treated with habitual medication was ac-
companied by pronounced levels of fatigue and emo-
tional problems, whereas this was not the case after
sumatriptan use. Problems regarding current pain,
general physical pain, and engaging in social activities
that are already present in interictal migraineurs, are
unaltered during the postattack period after habitual
medication use but significantly reduced after sumatrip-
tan use, which seems paradoxical. These results were in-
dicated by the CW charts, an instrument for the mea-
surement of general functional state, and the items
address the 2 weeks prior to completion. The patients
may base their judgment of health state on their ex-
periences during their latest attack rather than the
addressed period. The attacks that preceded the base-
line session and the postattack session after habitual
medication were both treated with the same medica-
tion, and, hence, the perceived health state in these con-
ditions was equivalent. Sumatriptan induces a shorter
attack duration; patients are probably debilitated for a
shorter period, and can resume social interactions and
normal functioning sooner. Solomon and colleagues26
found an improved health state after 6 months of suma-
triptan use, especially in physical aspects of role func-
tioning, bodily pain, and social functioning in very se-
vere and difficult-to-treat patients with migraine. The
present study suggests similar improvements in health
state during the postattack period after sumatriptan use.
Because it does not reduce attack frequency, and did
not reduce headache severity in the present study, the
reduced attack duration is probably a key factor in the
beneficial effects on postictal health state.
In short, headache-free patients with migraine re-
ported a lower health state compared with healthy con-
trols. In migraineurs, mood state (depression, anxiety,
and fatigue) rather than personality traits was associ-
ated with externalizing aspects of health state. Internal-
izing aspects of health state (fatigue and emotional
problems) were negatively affected by an attack when
untreated or treated with analgesics, whereas external-
izing aspects of health state (physical pain, social activi-
ties, and current pain) were similar to the migraine-free
period. In contrast, treatment with sumatriptan had
beneficial effects on both internalizing and externalizing
aspects of health state during the postictal period. The
present results suggest that effects induced by a preced-
ing attack as well as those of medication use should be
considered in future studies on health and mood state in
interictal migrainous patients.
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